Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with a number of individuals who presented data and spoke at the American Academy of Neurology Annual Meeting, on topics ranging from COVID-19's clinical presentation, overall trends in the care of patients with multiple sclerosis, the potential of regenerative medicine in traumatic brain injury, the real-world and long-term use of new therapy for Lennox-Gastaut syndrome, the optimal timing for the newest therapy in neuromyelitis optica spectrum disorder, the Axon Registry and incorporating EHR information into its data collection, and the impact of the pandemic on clinician burnout and mental health.
Note: As part of AAN policy for the Annual Meeting, all individuals were asked to remain masked throughout the week, so there may be some moments of muffled noises as participants adjust or shift their masks.
Those featured include (in order of appearance):
- Jennifer Frontera, MD
- Stephen Krieger, MD
- Peter McAllister, MD
- Kelly Knupp, MD, MSCS
- Bruce Cree, MD, PhD, MAS
- Shrujal Baxi, MD, MPH
- Indu Subramanian, MD.
Episode Breakdown:
- 1:50 – Jennifer Frontera, MD, on the long-term data collected on COVID-19 post-infection neurological sequelae.
- 9:55 – Stephen Krieger, MD, on the trends in thinking about multiple sclerosis pathogenesis and quality of life.
- 14:05 – Peter McAllister, MD, on the phase 2 STEMTRA trial of stem cell therapy in patients with traumatic brain injury.
- 16:45 – Kelly Knupp, MD, MSCS, on the long-term use of fenfluramine in Lennox-Gastaut syndrome and clinical pearls on titration.
- 19:00 – Bruce Cree, MD, PhD, MAS, on the effect of inebilizumab in patients with neuromyelitis optica spectrum disorder regardless of disease duration.
- 21:05 – Shrujal Baxi, MD, MPH, on the AAN's Axon Registry and how Verana Health is playing a role in data collection.
- 23:55 – Indu Subramanian, MD, on the effects of COVID-19 on physicians and clinicians and the difficulties that have challenged the field.
